Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

ViaCyte begins phase II study of VC01-103 in type 1 diabetes

Feb. 4, 2021

Crinetics initiates phase I study of CRN-04777

Feb. 4, 2021

Immunovant pauses dosing in trials of IMVT-1401

Feb. 2, 2021

Prothena plans phase III study of birtamimab for patients with Mayo stage IV AL amyloidosis

Feb. 2, 2021

FDA lifts clinical hold on ACTION-Galactosemia Kids pediatric study of AT-007

Feb. 1, 2021

Topline results from ENHANCE-IT study of Lypdiso in hypertriglyceridemia

Feb. 1, 2021

Small molecule BC-1618 prolongs Ampk biological activity by targeting Fbxo48

Feb. 1, 2021

FDA clears IND for phase I/II study of VX-880 stem cell-derived therapy for type 1 diabetes

Feb. 1, 2021

Sunshine Lake Pharma patents SGLT-1 inhibitors

Jan. 29, 2021

PRV-3279 prevents immunogenicity in a preclinical model of gene therapy for Pompe disease

Jan. 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...